Rabeprazol

Rabeprazole is a proton pump inhibitor (PPI) that is commonly used to reduce gastric acid production in the stomach. It is primarily prescribed for the treatment of gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and peptic ulcers. By inhibiting the H+/K+ ATPase enzyme system on parietal cells, rabeprazole effectively decreases the secretion of hydrochloric acid, providing relief from acid-related disorders.

Rabeprazole was developed in the late 1990s and gained approval for medical use in various countries. It is administered orally in the form of enteric-coated tablets, which protect the drug from gastric acid degradation. The onset of action is typically within one hour, with an effective duration of approximately 24 hours, making it suitable for once-daily dosing.

Common side effects of rabeprazole include headache, diarrhea, constipation, nausea, and abdominal pain. Long-term use has been associated with potential risks such as vitamin B12 deficiency, hypomagnesemia, and an increased likelihood of gastrointestinal infections like Clostridioides difficile. As with other PPIs, considerations regarding appropriate duration and dose are essential to minimize adverse effects.

Rabeprazole is generally well-tolerated and prescribed by healthcare professionals based on individual patient needs. It is metabolized primarily in the liver via the cytochrome P450 system, and drug interactions may occur with medications such as warfarin, methotrexate, and certain antiretrovirals. Proper medical supervision is advisable during therapy to manage potential interactions and monitor for adverse effects.